{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:08:27Z","timestamp":1782310107503,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["RC-2024-2790170"],"award-info":[{"award-number":["RC-2024-2790170"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Advanced age at diagnosis, comorbidities and invalidating symptoms can debilitate multiple myeloma (MM) and AL amyloidosis (AL) patients, potentially precluding access to optimal therapy. The\n                    <jats:italic>Associazione Italiana contro le Leucemie<\/jats:italic>\n                    ,\n                    <jats:italic>Linfomi e Mieloma<\/jats:italic>\n                    (AIL) has been providing home care to hematological patients in Italy since 1993. Between 2014 and 2023, 83 MM and AL patients received home infusion therapy through AIL in Bologna. Half were newly diagnosed, and half had undergone 1\u20137 prior lines of therapy. The median age was 79\u00a0years and 56% of patients had a performance status\u2009\u2265\u20092. The most frequently administered drugs included bortezomib (82%), daratumumab (14%), and bendamustine (9%). During the median 116-day therapy duration (range 1\u2013750), patients received a median of 12 drug administrations and 12 home visits (range 1\u201359). Two-thirds of the patients never attended the outpatient clinic during home therapy. Ten newly diagnosed transplant-eligible patients were able to receive standard induction, restore their performance status, and proceed to transplantation. Twenty-one newly diagnosed transplant-ineligible patients received bortezomib and dexamethasone (with or without melphalan). At relapse, they were able to receive outpatient infusion therapy in 5 out of 11 cases. Elderly, frail patients, and patients in later relapse stages could maintain their quality of life, avoiding distressing hospital visits and remaining at home with their families while still receiving active treatment. Home therapy proved feasible in the 22 patients with AL in this study as well. Despite\u00a0the limitations of a single-center retrospective data collection, our results show that home care in these patients is safe and feasible. We hope these preliminary findings may encourage the implementation of such programs by health policies in the future.\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01683-2","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:53:15Z","timestamp":1748303595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home"],"prefix":"10.1007","volume":"25","author":[{"given":"Flavia","family":"Bigi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Fiacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Restuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Masci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Mazzocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Puppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Sacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Manzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Iezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pantani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania Abd","family":"Alatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"1683_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.annonc.2020.11.014","volume":"17","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up y behalf of the EHA guidelines committee * and ESMO guidelines committee. Ann Oncol. 2021;17:234. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014.","journal-title":"Ann Oncol"},{"issue":"2","key":"1683_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ajh.27177","volume":"99","author":"MA Gertz","year":"2024","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol. 2024;99(2):309\u201324. https:\/\/doi.org\/10.1002\/ajh.27177.","journal-title":"Am J Hematol"},{"issue":"13","key":"1683_CR3","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood. 2015;125(13):2068\u201374. https:\/\/doi.org\/10.1182\/blood-2014-12-615187.","journal-title":"Blood"},{"issue":"9","key":"1683_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"issue":"7","key":"1683_CR5","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3109\/10428194.2015.1106531","volume":"57","author":"F Gentilini","year":"2016","unstructured":"Gentilini F, Brunetti G, Finsinger P, et al. Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a home care unit program. Leuk Lymphoma. 2016;57(7):1716\u20138. https:\/\/doi.org\/10.3109\/10428194.2015.1106531.","journal-title":"Leuk Lymphoma"},{"key":"1683_CR6","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.1016\/j.ejon.2022.102199","volume":"60","author":"J Kirkegaard","year":"2022","unstructured":"Kirkegaard J, Lundholm BW, Rosenberg T, Lund T, Gundesen MT, Dieperink KB. Home is best. Self-administration of subcutaneous Bortezomib at home in patients with multiple myeloma\u2014a mixed method study. Eur J Oncol Nurs. 2022;60:102199. https:\/\/doi.org\/10.1016\/j.ejon.2022.102199.","journal-title":"Eur J Oncol Nurs"},{"issue":"2","key":"1683_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/annonc\/mdv563","volume":"27","author":"A Lassalle","year":"2016","unstructured":"Lassalle A, Thomar\u00e9 P, Fronteau C, et al. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Ann Oncol. 2016;27(2):314\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdv563.","journal-title":"Ann Oncol"},{"issue":"2","key":"1683_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejon.2009.09.003","volume":"14","author":"T Meenaghan","year":"2010","unstructured":"Meenaghan T, O\u2019Dwyer M, Hayden P, Hayat A, Murray M, Dowling M. Home administration of bortezomib: making a difference to myeloma patients\u2019 lives. Eur J Oncol Nurs. 2010;14(2):134\u20136. https:\/\/doi.org\/10.1016\/j.ejon.2009.09.003.","journal-title":"Eur J Oncol Nurs"},{"issue":"12","key":"1683_CR9","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1007\/s00520-016-3363-3","volume":"24","author":"M Touati","year":"2016","unstructured":"Touati M, Lamarsalle L, Moreau S, et al. Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in outpatient hospital and hospital care at home. Support Care Cancer. 2016;24(12):5007\u201314. https:\/\/doi.org\/10.1007\/s00520-016-3363-3.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1683_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00520-021-06297-4","volume":"30","author":"G Fouquet","year":"2022","unstructured":"Fouquet G, Franchi P, Mittaine-Marzac B, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice. Support Care Cancer. 2022;30(2):973\u20135. https:\/\/doi.org\/10.1007\/s00520-021-06297-4.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1683_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12185-021-03219-2","volume":"115","author":"I G\u00f3mez-Centuri\u00f3n","year":"2022","unstructured":"G\u00f3mez-Centuri\u00f3n I, Oarbeascoa G, Garc\u00eda MC, et al. Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility. Int J Hematol. 2022;115(1):61\u20138. https:\/\/doi.org\/10.1007\/s12185-021-03219-2.","journal-title":"Int J Hematol"},{"issue":"6","key":"1683_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"1683_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1532-5415.1983.tb03391.x","volume":"31","author":"S Katz","year":"1983","unstructured":"Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc. 1983;31(12):721\u20137. https:\/\/doi.org\/10.1111\/j.1532-5415.1983.tb03391.x.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"1683_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179\u201386. https:\/\/doi.org\/10.1093\/geront\/9.3_Part_1.179.","journal-title":"Gerontologist"},{"issue":"8","key":"1683_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"1683_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103635","author":"S Guzzinati","year":"2024","unstructured":"Guzzinati S, Toffolutti F, Francisci S, et al. Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030. ESMO Open. 2024. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103635.","journal-title":"ESMO Open."},{"issue":"1","key":"1683_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 CA: a cancer. J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"J Clin"},{"issue":"9","key":"1683_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906\u201317. https:\/\/doi.org\/10.1056\/NEJMoa0801479.","journal-title":"N Engl J Med"},{"issue":"25","key":"1683_CR19","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271\u201380. https:\/\/doi.org\/10.1182\/blood.2019000834.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01683-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:51:35Z","timestamp":1764917495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01683-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katia Mancuso has received honoraria from Celgene, Takeda, Amgen, Sanofi and Janssen; Lucia Pantani has received honoraria from GlaxoSmithKline, Pfizer and Sanofi; Paola Tacchetti has received honoraria from Amgen, Bristol-Myers Squibb\/Celgene, Janssen, Takeda, AbbVie, Sanofi, GlaxoSmithKline and Pfizer; Michele Cavo has received honoraria and has served in a consulting\/advisory role for Amgen, AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Menarini-Stemline, Sanofi, and Karyopharm Therapeutics; Elena Zamagni has received honoraria and has served in advisory role for Janssen, Bristol-Myers Squibb, Sanofi, Amgen, GlaxoSmithKline, Pfizer, Oncopeptides, Menarini-Stemline; Ilaria Rizzello has received honoraria from Amgen, GlaxoSmithKline and Sanofi and advisory role for GlaxoSmithKline. Flavia Bigi, Mauro Fiacchini, Roberta Restuccia, Simone Masci, Gaia Mazzocchetti, Marco Talarico, Michele Puppi, Ilaria Sacchetti, Enrica Manzato, Miriam Iezza, Chiara Sartor, Rania Abd Alatif, Erica Pastore, and Simona Barbato declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by CE AVEC and conducted in accordance with the International Conference on Harmonization Guidelines on Good Clinical Practice and the principles of the Declaration of Helsinki. All participants signed an informed consent form prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"179"}}